AstraZeneca Pharma India gets NPPA Notice Over Alleged Overcharging of Inhaler Powder

AstraZeneca Pharma India Ltd. on Friday said it has received a show-cause notice from the National Pharmaceutical Pricing Authority (NPPA) alleging overcharging on its ‘Symbicort Turbuhaler’ inhalation powder.

The authority has claimed an implication of ₹604.98 million with interest, citing that batches of the product were priced above the notified ceiling level. Each inhaler powder contains 60 doses.

The company has been given 30 days to respond to the notice, AstraZeneca said in an exchange filing.